999 related articles for article (PubMed ID: 22476854)
1. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA
Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854
[TBL] [Abstract][Full Text] [Related]
2. Exploratory analysis of cardiac biomarkers in women with normal cardiac function receiving trastuzumab for breast cancer.
Goel S; Simes RJ; Beith JM
Asia Pac J Clin Oncol; 2011 Sep; 7(3):276-80. PubMed ID: 21884439
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer.
Şendur MA; Aksoy S; Yorgun H; Ozdemir N; Yilmaz FM; Yazıcı O; Zungun C; Aytemir K; Zengin N; Altundag K
Curr Med Res Opin; 2015 Mar; 31(3):547-56. PubMed ID: 25586297
[TBL] [Abstract][Full Text] [Related]
4. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib.
Morris PG; Chen C; Steingart R; Fleisher M; Lin N; Moy B; Come S; Sugarman S; Abbruzzi A; Lehman R; Patil S; Dickler M; McArthur HL; Winer E; Norton L; Hudis CA; Dang CT
Clin Cancer Res; 2011 May; 17(10):3490-9. PubMed ID: 21372222
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer.
Tarantini L; Cioffi G; Gori S; Tuccia F; Boccardi L; Bovelli D; Lestuzzi C; Maurea N; Oliva S; Russo G; Faggiano P;
J Card Fail; 2012 Feb; 18(2):113-9. PubMed ID: 22300778
[TBL] [Abstract][Full Text] [Related]
7. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors.
Farolfi A; Melegari E; Aquilina M; Scarpi E; Ibrahim T; Maltoni R; Sarti S; Cecconetto L; Pietri E; Ferrario C; Fedeli A; Faedi M; Nanni O; Frassineti GL; Amadori D; Rocca A
Heart; 2013 May; 99(9):634-9. PubMed ID: 23349345
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
Telli ML; Hunt SA; Carlson RW; Guardino AE
J Clin Oncol; 2007 Aug; 25(23):3525-33. PubMed ID: 17687157
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab-related cardiac events in the treatment of early breast cancer.
Fried G; Regev T; Moskovitz M
Breast Cancer Res Treat; 2013 Nov; 142(1):1-7. PubMed ID: 24154507
[TBL] [Abstract][Full Text] [Related]
11. Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer.
Russo G; Cioffi G; Gori S; Tuccia F; Boccardi L; Khoury G; Lestuzzi C; Maurea N; Oliva S; Faggiano P; Tarantini L;
J Cardiovasc Med (Hagerstown); 2014 Feb; 15(2):141-6. PubMed ID: 24534802
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation.
Cardinale D; Colombo A; Torrisi R; Sandri MT; Civelli M; Salvatici M; Lamantia G; Colombo N; Cortinovis S; Dessanai MA; Nolè F; Veglia F; Cipolla CM
J Clin Oncol; 2010 Sep; 28(25):3910-6. PubMed ID: 20679614
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab therapy in Australia: which patients with HER2+ metastatic breast cancer are assessed for cardiac function?
Lu CY; Srasuebkul P; Drew AK; Chen K; Ward RL; Pearson SA
Breast; 2013 Aug; 22(4):482-7. PubMed ID: 23664254
[TBL] [Abstract][Full Text] [Related]
14. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.
Sawaya H; Sebag IA; Plana JC; Januzzi JL; Ky B; Tan TC; Cohen V; Banchs J; Carver JR; Wiegers SE; Martin RP; Picard MH; Gerszten RE; Halpern EF; Passeri J; Kuter I; Scherrer-Crosbie M
Circ Cardiovasc Imaging; 2012 Sep; 5(5):596-603. PubMed ID: 22744937
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
Boekhout AH; Gietema JA; Milojkovic Kerklaan B; van Werkhoven ED; Altena R; Honkoop A; Los M; Smit WM; Nieboer P; Smorenburg CH; Mandigers CM; van der Wouw AJ; Kessels L; van der Velden AW; Ottevanger PB; Smilde T; de Boer J; van Veldhuisen DJ; Kema IP; de Vries EG; Schellens JH
JAMA Oncol; 2016 Aug; 2(8):1030-7. PubMed ID: 27348762
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity.
van Hasselt JG; Boekhout AH; Beijnen JH; Schellens JH; Huitema AD
Clin Pharmacol Ther; 2011 Jul; 90(1):126-32. PubMed ID: 21633346
[TBL] [Abstract][Full Text] [Related]
17. Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer.
Fiúza M
Adv Ther; 2009 Jul; 26 Suppl 1():S9-17. PubMed ID: 19669637
[TBL] [Abstract][Full Text] [Related]
18. Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy.
Zardavas D; Suter TM; Van Veldhuisen DJ; Steinseifer J; Noe J; Lauer S; Al-Sakaff N; Piccart-Gebhart MJ; de Azambuja E
J Clin Oncol; 2017 Mar; 35(8):878-884. PubMed ID: 28199174
[TBL] [Abstract][Full Text] [Related]
19. Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.
Seferina SC; de Boer M; Derksen MW; van den Berkmortel F; van Kampen RJ; van de Wouw AJ; Joore M; Peer PG; Voogd AC; Tjan-Heijnen VC
Oncologist; 2016 May; 21(5):555-62. PubMed ID: 27009939
[TBL] [Abstract][Full Text] [Related]
20. [Primary safety analysis of trastuzumab after adjuvant chemotherapy in 30 Chinese Her2-positive early breast cancer patients].
Zhou NN; Teng XY; Liu DG; Xu R; Guan ZZ
Ai Zheng; 2008 Dec; 27(12):1307-9. PubMed ID: 19079999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]